首页> Cancer research> Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma.

Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Ruzan,Udumyan

第一单位： Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden. Ruzan.Udumyan@oru.se.

作者： Ruzan,Udumyan ^[1] ; Scott,Montgomery ^[2] ; Fang,Fang ^[3] ; Henrik,Almroth ^[4] ; Unnur,Valdimarsdottir ^[5] ; Anders,Ekbom ^[6] ; Karin E,Smedby ^[7] ; Katja,Fall ^[8]

作者单位： Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden. Ruzan.Udumyan@oru.se. ^[1] Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.;Clinical Epidemiology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.;Department of Epidemiology and Public Health, University College London, London, United Kingdom. ^[2] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ^[3] Department of Cardiology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. ^[4] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Center of Public Health Sciences, University of Iceland, Reykjavik, Iceland.;Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. ^[5] Clinical Epidemiology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. ^[6] Clinical Epidemiology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.;Hematology Center, Karolinska University Hospital, Stockholm, Sweden. ^[7] Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ^[8]